A humanized glycoprotein VI (GPVI) mouse model to assess the antithrombotic efficacies of anti-GPVI agents

Journal of Pharmacology and Experimental Therapeutics

Volumn 341, Issue 1, 2012, Pages 156-163

  Mangin, Pierre Henri ^a,b,c   Tang, ChaoJun ^a,b,c   Bourdon, Catherine ^a,b,c   Loyau, Stéphane ^a,d,e   Freund, Monique ^a,b,c   Hechler, Béatrice ^a,b,c   Gachet, Christian ^a,b,c   Jandrot Perrus, Martine ^a,d,e  

^a INSERM   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c ETABLISSEMENT FRANÇAIS DU SANG   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTITHROMBOCYTIC AGENT; COLLAGEN; FIBRINOGEN; GLYCOPROTEIN VI; GLYCOPROTEIN VI INHIBITOR; HIRUDIN; IMMUNOGLOBULIN F(AB) FRAGMENT; PADGEM PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; EX VIVO STUDY; HEMATOLOGICAL PARAMETERS; IN VITRO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE MEMBRANE; THROMBOEMBOLISM; TRANSGENIC ORGANISM;

ANIMALS; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; GENE KNOCK-IN TECHNIQUES; HUMANS; MICE; MICE, TRANSGENIC; PLATELET MEMBRANE GLYCOPROTEINS; THROMBOSIS; TREATMENT OUTCOME;

EID: 84858687801     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.189050     Document Type: Article

References (26)

1. Bender M, Hagedorn I, and Nieswandt B (2011) Genetic and antibody-induced glycoprotein VI deficiency equally protects mice from mechanically and FeCl(3)-induced thrombosis. J Thromb Haemost 9:1423-1426.
2. Best D, Senis YA, Jarvis GE, Eagleton HJ, Roberts DJ, Saito T, Jung SM, Moroi M, Harrison P, Green FR, et al. (2003) GPVI levels in platelets: relationship to platelet function at high shear. Blood 102:2811-2818. (Pubitemid 37248851)
3. Bigalke B, Krämer BF, Seizer P, Fateh-Moghadam S, Gawaz M, and Lindemann S (2010) Diagnostic and therapeutic potentials of platelet glycoprotein VI. Semin Thromb Hemost 36:203-211.
4. Cosemans JM, Kuijpers MJ, Lecut C, Loubele ST, Heeneman S, Jandrot-Perrus M, and Heemskerk JW (2005) Contribution of platelet glycoprotein VI to the thrombogenic effect of collagens in fibrous atherosclerotic lesions. Atherosclerosis 181: 19-27. (Pubitemid 40804689)
5. DiMinno G and Silver MJ (1983) Mouse antithrombotic assay: a simple method for the evaluation of antithrombotic agents in vivo. Potentiation of antithrombotic activity by ethyl alcohol. J Pharmacol Exp Ther 225:57-60. (Pubitemid 13137003)
6. Dumont B, Lasne D, Rothschild C, Bouabdelli M, Ollivier V, Oudin C, Ajzenberg N, Grandchamp B, and Jandrot-Perrus M (2009) Absence of collagen-induced platelet activation caused by compound heterozygous GPVI mutations. Blood 114:1900-1903.
7. Hechler B and Gachet C (2011) Comparison of two murine models of thrombosis induced by atherosclerotic plaque injury. Thromb Haemost 105 (Suppl 1):S3-S12.
8. Hechler B, Nonne C, Eckly A, Magnenat S, Rinckel JY, Denis CV, Freund M, Cazenave JP, Lanza F, and Gachet C (2010) Arterial thrombosis: relevance of a model with two levels of severity assessed by histologic, ultrastructural and functional characterization. J Thromb Haemost 8:173-184.
9. Jackson SP and Schoenwaelder SM (2003) Antiplatelet therapy: in search of the 'magic bullet.' Nat Rev Drug Discov 2:775-789. (Pubitemid 37361810)
10. Jandrot-Perrus M, Busfield S, Lagrue AH, Xiong X, Debili N, Chickering T, Le Couedic JP, Goodearl A, Dussault B, Fraser C, et al. (2000) Cloning, characterization, and functional studies of human and mouse glycoprotein VI: a platelet-specific collagen receptor from the immunoglobulin superfamily. Blood 96:1798-1807. (Pubitemid 30661064)
11. Kuijpers MJ, Gilio K, Reitsma S, Nergiz-Unal R, Prinzen L, Heeneman S, Lutgens E, van Zandvoort MA, Nieswandt B, Egbrink MG, et al. (2009) Complementary roles of platelets and coagulation in thrombus formation on plaques acutely ruptured by targeted ultrasound treatment: a novel intravital model. J Thromb Haemost 7:152-161.
12. Lecut C, Feeney LA, Kingsbury G, Hopkins J, Lanza F, Gachet C, Villeval JL, and Jandrot-Perrus M (2003) Human platelet glycoprotein VI function is antagonized by monoclonal antibody-derived Fab fragments. J Thromb Haemost 1:2653-2662.
13. Léon C, Eckly A, Hechler B, Aleil B, Freund M, Ravanat C, Jourdain M, Nonne C, Weber J, Tiedt R, et al. (2007) Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion. Blood 110:3183-3191. (Pubitemid 350106310)
14. Mangin P, Yap CL, Nonne C, Sturgeon SA, Goncalves I, Yuan Y, Schoenwaelder SM, Wright CE, Lanza F, and Jackson SP (2006) Thrombin overcomes the thrombosis defect associated with platelet GPVI/FcRgamma deficiency. Blood 107:4346-4353. (Pubitemid 43801360)
15. Massberg S, Konrad I, Bültmann A, Schulz C, Münch G, Peluso M, Lorenz M, Schneider S, Besta F, Müller I, et al. (2004) Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J 18:397-399.
16. Nonne C, Lenain N, Hechler B, Mangin P, Cazenave JP, Gachet C, and Lanza F (2005) Importance of platelet phospholipase Cgamma2 signaling in arterial thrombosis as a function of lesion severity. Arterioscler Thromb Vasc Biol 25:1293-1298. (Pubitemid 40776624)
17. Nurden P, Tandon N, Takizawa H, Couzi L, Morel D, Fiore M, Pillois X, Loyau S, Jandrot-Perrus M, and Nurden AT (2009) An acquired inhibitor to the GPVI platelet collagen receptor in a patient with lupus nephritis. J Thromb Haemost 7:1541-1549.
18. Ohlmann P, Hechler B, Ravanat C, Loyau S, Herrenschmidt N, Wanert F, Jandrot-Perrus M, and Gachet C (2008) Ex vivo inhibition of thrombus formation by an anti-glycoprotein VI Fab fragment in non-human primates without modification of glycoprotein VI expression. J Thromb Haemost 6:1003-1011. (Pubitemid 351689923)
19. Rabie T, Varga-Szabo D, Bender M, Pozgaj R, Lanza F, Saito T, Watson SP, and Nieswandt B (2007) Diverging signaling events control the pathway of GPVI down-regulation in vivo. Blood 110:529-535. (Pubitemid 47105390)
20. Reininger AJ, Bernlochner I, Penz SM, Ravanat C, Smethurst P, Farndale RW, Gachet C, Brandl R, and SiessW(2010)A2-stepmechanism of arterial thrombus formation induced by human atherosclerotic plaques. J Am Coll Cardiol 55:1147-1158.
21. -/- mice. Cardiovasc Res 80:131-137.
22. Smethurst PA, Joutsi-Korhonen L, O'Connor MN, Wilson E, Jennings NS, Garner SF, Zhang Y, Knight CG, Dafforn TR, Buckle A, et al. (2004) Identification of the primary collagen-binding surface on human glycoprotein VI by site-directed mutagenesis and by a blocking phage antibody. Blood 103:903-911. (Pubitemid 38129549)
23. Sugiyama T, Okuma M, Ushikubi F, Sensaki S, Kanaji K, and Uchino H (1987) A novel platelet aggregating factor found in a patient with defective collagen-induced platelet aggregation and autoimmune thrombocytopenia. Blood 69:1712-1720. (Pubitemid 17091630)
24. Takayama H, Hosaka Y, Nakayama K, Shirakawa K, Naitoh K, Matsusue T, Shinozaki M, Honda M, Yatagai Y, Kawahara T, et al. (2008) A novel antiplatelet antibody therapy that induces cAMP-dependent endocytosis of the GPVI/Fc receptor gamma-chain complex. J Clin Invest 118:1785-1795. (Pubitemid 351632381)
25. Ungerer M, Rosport K, Bültmann A, Piechatzek R, Uhland K, Schlieper P, Gawaz M, and Münch G (2011) Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation 123:1891-1899.
26. Yousuf O and Bhatt DL (2011) The evolution of antiplatelet therapy in cardiovascular disease. Nat Rev Cardiol 8: 547-559.